Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5475)
All Articles published online
|
Jun 21, 2012 (publication date) through May 1, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Pichai MV, Ferguson LR. Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases. World J Gastroenterol 2012; 18(23): 2895-2901 [PMID: 22736912 DOI: 10.3748/wjg.v18.i23.2895] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v18/i23/2895.htm |
| Number | Citing Articles |
| 1 |
Dongwei Guo, JoEllyn M. McMillan, Howard E. Gendelman. Handbook of Neurotoxicity. 2014; : 2125 doi: 10.1007/978-1-4614-5836-4_116
|
| 2 |
Mahira Zeeshan, Hussain Ali, Salman Khan, Saeed Ahmad Khan, Benno Weigmann. Advances in orally-delivered pH-sensitive nanocarrier systems; an optimistic approach for the treatment of inflammatory bowel disease. International Journal of Pharmaceutics 2019; 558: 201 doi: 10.1016/j.ijpharm.2018.12.074
|
| 3 |
Angelo Viscido, Annalisa Capannolo, Giovanni Latella, Renzo Caprilli, Giuseppe Frieri. Nanotechnology in the treatment of inflammatory bowel diseases. Journal of Crohn's and Colitis 2014; 8(9): 903 doi: 10.1016/j.crohns.2014.02.024
|
| 4 |
Juan C Andreu-Ballester, Rafael Gil-Borrás, Carlos García-Ballesteros, Ignacio Catalán-Serra, Victoria Amigo, Virgina Fernández-Fígares, Carmen Cuéllar. Epstein-Barr virus is related with 5-aminosalicylic acid, tonsillectomy, and CD19<sup>+</sup> cells in Crohn’s disease. World Journal of Gastroenterology 2015; 21(15): 4666-4672 doi: 10.3748/wjg.v21.i15.4666
|
| 5 |
Sumit Sharma, Vivek R. Sinha. Current pharmaceutical strategies for efficient site specific delivery in inflamed distal intestinal mucosa. Journal of Controlled Release 2018; 272: 97 doi: 10.1016/j.jconrel.2018.01.003
|
| 6 |
Yongfeng Zhang, Yaqin Zhang, Yang Zhao, Wanyue Wu, Weiqi Meng, Yulin Zhou, Ye Qiu, Chenliang Li. Protection against ulcerative colitis and colorectal cancer by evodiamine via anti‑inflammatory effects. Molecular Medicine Reports 2022; 25(5) doi: 10.3892/mmr.2022.12704
|
| 7 |
Izabela B.C. Lima, Lina Clara.G.A.I. Moreno, Edson C. Silva-Filho, Juan M. Irache, Francisco J.B. Veiga, Hercília M.L. Rolim, Lívio C.C. Nunes. Development of nanostructured systems using natural polymers to optimize the treatment of inflammatory bowel diseases: A prospective study. Journal of Drug Delivery Science and Technology 2021; 64: 102590 doi: 10.1016/j.jddst.2021.102590
|
| 8 |
Mohammed N. Khan, Majella E. Lane, Paul A. McCarron, Murtaza M. Tambuwala. Caffeic acid phenethyl ester is protective in experimental ulcerative colitis via reduction in levels of pro-inflammatory mediators and enhancement of epithelial barrier function. Inflammopharmacology 2018; 26(2): 561 doi: 10.1007/s10787-017-0364-x
|
| 9 |
Narenda Kumar, Rajiv Kumar. Nanotechnology and Nanomaterials in the Treatment of Life-threatening Diseases. 2014; : 347 doi: 10.1016/B978-0-323-26433-4.00007-5
|
| 10 |
Joana Torres, Silvio Danese, Jean-Frédéric Colombel. New therapeutic avenues in ulcerative colitis: thinking out of the box. Gut 2013; 62(11): 1642 doi: 10.1136/gutjnl-2012-303959
|
| 11 |
Shanshan Li, Fuzhong Zhang, Qixiong Zhang. Pathological features-based targeted delivery strategies in IBD therapy: A mini review. Biomedicine & Pharmacotherapy 2022; 151: 113079 doi: 10.1016/j.biopha.2022.113079
|
| 12 |
Federica Di Vincenzo, Ylenia Yadid, Valentina Petito, Valeria Emoli, Letizia Masi, Daniela Gerovska, Marcos Jesus Araúzo-Bravo, Antonio Gasbarrini, Birgitte Regenberg, Franco Scaldaferri. Circular and Circulating DNA in Inflammatory Bowel Disease: From Pathogenesis to Potential Molecular Therapies. Cells 2023; 12(15): 1953 doi: 10.3390/cells12151953
|
| 13 |
Nidhi Mishra, Samipta Singh, Priyanka Maurya, Raquibun Nisha, Shubhini A. Saraf. Nanoformulations in Human Health. 2020; : 133 doi: 10.1007/978-3-030-41858-8_7
|
| 14 |
Danish J. Malik, Ilya J. Sokolov, Gurinder K. Vinner, Francesco Mancuso, Salvatore Cinquerrui, Goran T. Vladisavljevic, Martha R.J. Clokie, Natalie J. Garton, Andrew G.F. Stapley, Anna Kirpichnikova. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Advances in Colloid and Interface Science 2017; 249: 100 doi: 10.1016/j.cis.2017.05.014
|
| 15 |
Shaoxin Wang, Jiang Pu, Na Li, Chuanfeng Li, Chao Li, Lan Yu, Xiaohui Wang, Shanfeng Fu, Lihong Cui. CUEDC2 Protects Against Experimental Colitis and Suppresses Excessive Proliferation of Intestinal Mucosa. Digestive Diseases and Sciences 2015; 60(12): 3603 doi: 10.1007/s10620-015-3800-z
|
| 16 |
Hicheme Hadji, Kawthar Bouchemal. Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems. Advanced Drug Delivery Reviews 2022; 181: 114101 doi: 10.1016/j.addr.2021.114101
|
| 17 |
Limei Zhou, Yunxia Shang, Yaru Wang, Xiaohui Wei. Transferrin modified PEG–PLGA nanoparticles: highly effective notoginsenoside R1 formulations for the treatment of ulcerative colitis. Journal of Pharmaceutical Investigation 2024; 54(3): 357 doi: 10.1007/s40005-023-00657-4
|
| 18 |
Shaoxin Wang, Jiang Pu, Xiaowei Li, Zhihui Yan, Chao Li, Yan Zheng, Zhe Luo, Lihong Cui. UBE2W Improves the Experimental Colitis by Inhibiting the NF-κB Signaling Pathway. Digestive Diseases and Sciences 2022; 67(12): 5529 doi: 10.1007/s10620-022-07453-4
|
| 19 |
Panpan Ma, Xiaoying Si, Qiubing Chen, Lijun Ma, Meili Hou, Zhigang Xu, Yuejun Kang, Jianglin Wang, Bo Xiao. Oral Drug Delivery Systems for Ulcerative Colitis Therapy: A Comparative Study with Microparticles and Nanoparticles. Current Cancer Drug Targets 2019; 19(4): 304 doi: 10.2174/1568009618666181016152042
|
| 20 |
Konstantinos H Katsanos, Konstantinos A Papadakis. Pharmacogenetics of inflammatory bowel disease. Pharmacogenomics 2014; 15(16): 2049 doi: 10.2217/pgs.14.154
|
| 21 |
Maia Merabishvili, Jean-Paul Pirnay, Kilian Vogele, Danish J. Malik. Phage Therapy: A Practical Approach. 2019; : 3 doi: 10.1007/978-3-030-26736-0_1
|
| 22 |
Fengqian Chen, Qi Liu, Yang Xiong, Li Xu. Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease. International Journal of Nanomedicine 2021; : 4225 doi: 10.2147/IJN.S310952
|
| 23 |
Shatadal Ghosh, Sumit Ghosh, Parames C. Sil. Role of nanostructures in improvising oral medicine. Toxicology Reports 2019; 6: 358 doi: 10.1016/j.toxrep.2019.04.004
|
| 24 |
Remya Sreedhar, Somasundaram Arumugam, Rajarajan A. Thandavarayan, Vijayasree V. Giridharan, Vengadeshprabhu Karuppagounder, Vigneshwaran Pitchaimani, Rejina Afrin, Meilei Harima, Takashi Nakamura, Kazuyuki Ueno, Masahiko Nakamura, Kenji Suzuki, Kenichi Watanabe. Toki-shakuyaku-san, a Japanese kampo medicine, reduces colon inflammation in a mouse model of acute colitis. International Immunopharmacology 2015; 29(2): 869 doi: 10.1016/j.intimp.2015.08.029
|
| 25 |
Ole Haagen Nielsen. New Strategies for Treatment of Inflammatory Bowel Disease. Frontiers in Medicine 2014; 1 doi: 10.3389/fmed.2014.00003
|
| 26 |
Bomy Lee Chung, Michael J. Toth, Nazila Kamaly, Yoshitaka J. Sei, Jacob Becraft, Willem J.M. Mulder, Zahi A. Fayad, Omid C. Farokhzad, YongTae Kim, Robert Langer. Nanomedicines for endothelial disorders. Nano Today 2015; 10(6): 759 doi: 10.1016/j.nantod.2015.11.009
|
| 27 |
Susan Hua, Ellen Marks, Jennifer J. Schneider, Simon Keely. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: Selective targeting to diseased versus healthy tissue. Nanomedicine: Nanotechnology, Biology and Medicine 2015; 11(5): 1117 doi: 10.1016/j.nano.2015.02.018
|
| 28 |
Arivarasu N. Anbazhagan, Mentor Thaqi, Shubha Priyamvada, Dulari Jayawardena, Anoop Kumar, Tarunmeet Gujral, Ishita Chatterjee, Edurne Mugarza, Seema Saksena, Hayat Onyuksel, Pradeep K. Dudeja. GLP-1 nanomedicine alleviates gut inflammation. Nanomedicine: Nanotechnology, Biology and Medicine 2017; 13(2): 659 doi: 10.1016/j.nano.2016.08.004
|
| 29 |
Eden Mariam Jacob, Ankita Borah, Sindhu C Pillai, D. Sakthi Kumar. Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy. Nanomaterials 2020; 10(12): 2460 doi: 10.3390/nano10122460
|
| 30 |
Shangwen Zhang, Li Kang, Sheng Hu, Jie Hu, Yanping Fu, Yan Hu, Xinzhou Yang. Carboxymethyl chitosan microspheres loaded hyaluronic acid/gelatin hydrogels for controlled drug delivery and the treatment of inflammatory bowel disease. International Journal of Biological Macromolecules 2021; 167: 1598 doi: 10.1016/j.ijbiomac.2020.11.117
|
| 31 |
F. Talaei, F. Atyabi, M. Azhdarzadeh, R. Dinarvand, A. Saadatzadeh. Overcoming therapeutic obstacles in inflammatory bowel diseases: A comprehensive review on novel drug delivery strategies. European Journal of Pharmaceutical Sciences 2013; 49(4): 712 doi: 10.1016/j.ejps.2013.04.031
|
| 32 |
Nithin B Boppana, Asokan Devarajan, Kaliappan Gopal, Muttiah Barathan, Sazaly A Bakar, Esaki M Shankar, Abdul S Ebrahim, Shukkur M Farooq. Blockade of CXCR2 signalling: A potential therapeutic target for preventing neutrophil-mediated inflammatory diseases. Experimental Biology and Medicine 2014; 239(5): 509 doi: 10.1177/1535370213520110
|
| 33 |
Yue Hu, Meng Li, Bin Lu, Xi Wang, Chaoying Chen, Meng Zhang. Corticotropin-releasing factor augments LPS-induced immune/inflammatory responses in JAWSII cells. Immunologic Research 2016; 64(2): 540 doi: 10.1007/s12026-015-8740-3
|